MapLight Therapeutics, Inc. (MPLT)
NASDAQ: MPLT · Real-Time Price · USD
30.05
+1.54 (5.40%)
Apr 17, 2026, 4:00 PM EDT - Market closed
MapLight Therapeutics Employees
MapLight Therapeutics had 133 employees as of December 31, 2025. The number of employees increased by 70 or 111.11% compared to the previous year.
Employees
133
Change
70
Growth
111.11%
Revenue / Employee
n/a
Profits / Employee
-$1,211,669
Market Cap
1.32B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 133 | 30 | 29.13% |
| Sep 30, 2025 | 114 | - | - |
| Jun 30, 2025 | 109 | 35 | 47.30% |
| Mar 31, 2025 | 103 | 29 | 39.19% |
| Mar 31, 2024 | 74 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| AbCellera Biologics | 562 |
| Pharming Group | 407 |
| EyePoint | 214 |
| Zenas BioPharma | 167 |
| Maze Therapeutics | 141 |
| MoonLake Immunotherapeutics | 130 |
| DBV Technologies | 117 |
| Inhibrx Biosciences | 110 |
MPLT News
- 11 days ago - MapLight's Psychosis Drug Could Deliver Billion-Dollar Upside, Says Analyst - Benzinga
- 24 days ago - MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - MapLight Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026 - GlobeNewsWire
- 3 months ago - MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease Psychosis - GlobeNewsWire
- 4 months ago - SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies - GlobeNewsWire
- 4 months ago - MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress - GlobeNewsWire
- 6 months ago - MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire